• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

使用“断点棋盘平板”筛选针对产金属β-内酰胺酶的多重耐药铜绿假单胞菌的单环β-内酰胺类与氨基糖苷类联合治疗

Monobactam and aminoglycoside combination therapy against metallo-beta-lactamase-producing multidrug-resistant Pseudomonas aeruginosa screened using a 'break-point checkerboard plate'.

作者信息

Araoka Hideki, Baba Masaru, Takagi Shinsuke, Matsuno Naofumi, Ishiwata Kazuya, Nakano Nobuaki, Tsuji Masanori, Yamamoto Hisashi, Seo Sachiko, Asano-Mori Yuki, Uchida Naoyuki, Masuoka Kazuhiro, Wake Atsushi, Taniguchi Shuichi, Yoneyama Akiko

机构信息

Department of Infectious Diseases, Toranomon Hospital, Tokyo, Japan.

出版信息

Scand J Infect Dis. 2010 Mar;42(3):231-3. doi: 10.3109/00365540903443157.

DOI:10.3109/00365540903443157
PMID:20001223
Abstract

Metallo-beta-lactamase-producing multidrug-resistant Pseudomonas aeruginosa (MDR P. aeruginosa) is a cause of life-threatening infections. With parenteral colistin not available in Japan, we treated MDR P. aeruginosa sepsis with monobactam and aminoglycoside combination therapy, with screening using a 'break-point checkerboard plate'.

摘要

产金属β-内酰胺酶的多重耐药铜绿假单胞菌（MDR P. aeruginosa）是危及生命感染的一个病因。由于日本没有胃肠外使用的黏菌素，我们采用单环β-内酰胺类抗生素与氨基糖苷类抗生素联合疗法治疗MDR P. aeruginosa败血症，并使用“断点棋盘格平板”进行筛选。

相似文献

1
Monobactam and aminoglycoside combination therapy against metallo-beta-lactamase-producing multidrug-resistant Pseudomonas aeruginosa screened using a 'break-point checkerboard plate'.使用“断点棋盘平板”筛选针对产金属β-内酰胺酶的多重耐药铜绿假单胞菌的单环β-内酰胺类与氨基糖苷类联合治疗
Scand J Infect Dis. 2010 Mar;42(3):231-3. doi: 10.3109/00365540903443157.
2
Dissemination in Japan of multidrug-resistant Pseudomonas aeruginosa isolates producing IMP-type metallo-β-lactamases and AAC(6')-Iae/AAC(6')-Ib.在日本传播产IMP型金属β-内酰胺酶和AAC(6')-Iae/AAC(6')-Ib的多重耐药铜绿假单胞菌分离株
J Infect Chemother. 2014 Sep;20(9):586-8. doi: 10.1016/j.jiac.2014.04.014. Epub 2014 Jun 6.
3
'Break-point Checkerboard Plate' for screening of appropriate antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa.用于筛选针对多重耐药铜绿假单胞菌的合适抗生素组合的“断点棋盘格平板”
Scand J Infect Dis. 2006;38(4):268-72. doi: 10.1080/00365540500440353.
4
In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.非传统抗菌药物单独或联合使用对从重症监护病房分离出的多重耐药铜绿假单胞菌和鲍曼不动杆菌菌株的体外活性。
Int J Antimicrob Agents. 2006 Mar;27(3):224-8. doi: 10.1016/j.ijantimicag.2005.10.012. Epub 2006 Feb 7.
5
[Resistance caused by hyperproduction of chromosomal beta-lactamase in Pseudomonas aeruginosa].[铜绿假单胞菌中染色体β-内酰胺酶超量产生所致的耐药性]
Enferm Infecc Microbiol Clin. 1989 Dec;7(10):530-4.
6
Multidrug-resistant Pseudomonas aeruginosa isolate co-expressing extended-spectrum beta-lactamase PER-1 and metallo-beta-lactamase VIM-2 from Turkey.来自土耳其的共表达超广谱β-内酰胺酶PER-1和金属β-内酰胺酶VIM-2的多重耐药铜绿假单胞菌分离株。
J Antimicrob Chemother. 2008 Jan;61(1):221-2. doi: 10.1093/jac/dkm420. Epub 2007 Nov 2.
7
In vitro and in vivo potency of polymyxin B against IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa.多粘菌素B对产IMP型金属β-内酰胺酶的铜绿假单胞菌的体外和体内抗菌效力
Int J Antimicrob Agents. 2008 Nov;32(5):437-40. doi: 10.1016/j.ijantimicag.2008.05.006. Epub 2008 Aug 19.
8
[Case of sepsis caused by multidrug-resistant neutropenic-phase Pseudomonas aeruginosa treated successfully with antibiotic combination therapy].[多重耐药性中性粒细胞减少期铜绿假单胞菌引起脓毒症的病例经抗生素联合治疗成功治愈]
Kansenshogaku Zasshi. 2008 Sep;82(5):466-70. doi: 10.11150/kansenshogakuzasshi1970.82.466.
9
Effectiveness of antibiotic combination therapy as evaluated by the Break-point Checkerboard Plate method for multidrug-resistant Pseudomonas aeruginosa in clinical use.采用断点棋盘法评估临床使用的多药耐药铜绿假单胞菌抗生素联合治疗的有效性。
J Infect Chemother. 2014 Apr;20(4):266-9. doi: 10.1016/j.jiac.2013.12.005. Epub 2014 Jan 31.
10
Occurrence of antipseudomonal beta-lactams and aminoglycosides resistance in Pseudomonas aeruginosa during therapy.治疗期间铜绿假单胞菌对抗假单胞菌β-内酰胺类药物和氨基糖苷类药物耐药性的出现情况。
Microbiologica. 1987 Jan;10(1):103-10.

引用本文的文献

1
Small-molecule strategies to combat antibiotic resistance: mechanisms, modifications, and contemporary approaches.对抗抗生素耐药性的小分子策略：作用机制、修饰及当代方法
RSC Adv. 2025 Jul 14;15(30):24450-24474. doi: 10.1039/d5ra04047g. eCollection 2025 Jul 10.
2
Clinical Usefulness of Arbekacin.阿贝卡星的临床应用价值
Infect Chemother. 2016 Mar;48(1):1-11. doi: 10.3947/ic.2016.48.1.1. Epub 2016 Mar 31.
3
Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens.
阿贝卡星：一种用于治疗耐甲氧西林金黄色葡萄球菌和多重耐药革兰氏阴性病原体所致感染的新型药物。
Clin Pharmacol. 2014 Sep 26;6:139-48. doi: 10.2147/CPAA.S44377. eCollection 2014.
4
New options of antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa.针对多重耐药铜绿假单胞菌的抗生素联合治疗新方案。
Eur J Clin Microbiol Infect Dis. 2015 Jan;34(1):83-87. doi: 10.1007/s10096-014-2192-x. Epub 2014 Jul 29.